PeproMene Bio

Focus: PeproMene Bio is a CAR-T cell therapy biotech founded in 2017, focused on oncology and cell therapy applications with a pipeline targeting hematologic malignancies. The company is pre-revenue and early-stage, currently advancing BAFFR-CAR T cell candidates in Phase 1 development.

Oncology Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Total Funding

$11M

Open Jobs

About PeproMene Bio

AI assessmentNot Hiring

No open roles listed right now. Follow PeproMene Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BAFFR-CAR T cells

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1

Clinical Trials (1)

NCT05370430BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Phase 1

Help build intelligence for PeproMene Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep focus on CAR-T cell therapy, a high-value oncology modality with significant clinical upside and commercial potential
Early-stage company offers meaningful opportunity to shape scientific and clinical strategy in an emerging field
Irvine, CA location provides access to Southern California biotech ecosystem and talent pool

Watch Out For

Pre-revenue status with no disclosed funding creates uncertainty around runway and financial stability
Zero active job openings at time of data collection suggests minimal near-term hiring or potential organizational challenges
Only 2 Phase 1 programs with no advanced pipeline progression limits near-term value inflection catalysts

Generated by Claude from PeproMene Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BAFFR-CAR T cells

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Phase 1

Clinical Trials (1)

NCT04690595BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2017

Portfolio: 2 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline